Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Recommendation of “Hold” by Analysts

Gossamer Bio, Inc. (NASDAQ:GOSS) has received an average recommendation of “Hold” from the ten ratings firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $5.00.

Several brokerages have recently weighed in on GOSS. Royal Bank Of Canada upgraded shares of Gossamer Bio to an “outperform” rating in a research note on Tuesday, February 24th. Oppenheimer decreased their price target on shares of Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating on the stock in a research report on Thursday, March 5th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Gossamer Bio in a report on Tuesday, May 26th. Leerink Partners cut Gossamer Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, The Goldman Sachs Group downgraded Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th.

Gossamer Bio Price Performance

NASDAQ GOSS opened at $0.18 on Friday. Gossamer Bio has a 1-year low of $0.14 and a 1-year high of $3.87. The business’s fifty day moving average price is $0.30 and its 200-day moving average price is $1.50. The stock has a market capitalization of $41.64 million, a price-to-earnings ratio of -0.22 and a beta of 2.00.

Gossamer Bio (NASDAQ:GOSS) last posted its earnings results on Friday, May 15th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $16.96 million during the quarter, compared to the consensus estimate of $4.67 million. Equities research analysts anticipate that Gossamer Bio will post -0.45 EPS for the current year.

Institutional Investors Weigh In On Gossamer Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GOSS. Legal & General Group Plc bought a new stake in shares of Gossamer Bio during the 2nd quarter valued at $26,000. Banco BTG Pactual S.A. bought a new stake in Gossamer Bio during the second quarter valued at about $27,000. MMA Asset Management LLC bought a new stake in Gossamer Bio during the fourth quarter valued at about $31,000. Soltis Investment Advisors LLC bought a new stake in Gossamer Bio during the fourth quarter valued at about $31,000. Finally, Beacon Pointe Advisors LLC bought a new stake in Gossamer Bio during the 4th quarter valued at approximately $34,000. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.